Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 8/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | USP1 | O94782 | 2/20 | 0.41 |
| ▸ | WDR48 | Q8TAF3 | 2/20 | 0.41 |
| ▸ | GSK3A | P49840 | 6/20 | 0.41 |
| ▸ | GSK3B | P49841 | 6/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12303151 | 0.86 | PIP4K2C (0.45) | CYP1A2CYP2C19CYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL959116 | 0.85 | GSK3A (0.57) | CYP1A2CYP2C19CYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL2449058 | 0.84 | USP1 (0.43) | CYP1A2CYP2C19CYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL13854123 | 0.84 | MAPT (0.41) | ALDH1A1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL786723 | 0.83 | CYP1A2 (0.45) | CYP1A2CYP2C19CYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL12303144 | 0.79 | CYP1A2 (0.39) | CYP1A2CYP2C19CYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL802778 | 0.75 | LMNA (0.45) | CYP1A2CYP2C19CYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL961789 | 0.74 | PIP4K2C (0.43) | CYP1A2CYP2C19CYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL12914219 | 0.74 | PIP4K2C (0.47) | CYP1A2CYP2C19CYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL11917643 | 0.73 | GSK3A (0.62) | GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2176261-B1 | PROCESS FOR PREPARING 5-FLUORO-1H-PYRAZOLO [3, 4-B] PYRIDIN-3-AMINE AND DERIVATIVES THEREOF | VERTEX PHARMA (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120232275-A1 | PROCESS FOR PREPARING 5-FLUORO-1H-PYRAZOLO [3,4-B] PYRIDIN-3-AMINE AND DERIVATIVES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120232275-A1 | PROCESS FOR PREPARING 5-FLUORO-1H-PYRAZOLO [3,4-B] PYRIDIN-3-AMINE AND DERIVATIVES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-13 | — | — | US | disclosed |
| US-8242272-B2 | Process for preparing 5-fluoro-1H-pyrazolo [3,4-B] pyridin-3-amine and derivatives thereof | VERTEX PHARMACEUTICALS INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242272-B2 | Process for preparing 5-fluoro-1H-pyrazolo [3,4-B] pyridin-3-amine and derivatives thereof | VERTEX PHARMACEUTICALS INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-7872129-B2 | Compositions useful as inhibitors of GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-18 | — | — | US | disclosed |
| US-7872129-B2 | Compositions useful as inhibitors of GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-18 | — | — | US | disclosed |
| US-20100184980-A1 | Process for Preparing 5-Fluoro-1H-Pyrazolo [3,4-b] Pyridin-3-amine and Derivatives Thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2010-07-22 | — | — | US | disclosed |
| US-20100184980-A1 | Process for Preparing 5-Fluoro-1H-Pyrazolo [3,4-b] Pyridin-3-amine and Derivatives Thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2010-07-22 | — | — | US | disclosed |
| US-20090118278-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-05-07 | — | — | US | disclosed |
| US-20090118278-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-05-07 | — | — | US | disclosed |
| US-7491730-B2 | Compositions useful as inhibitors of GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-17 | — | — | US | disclosed |
| US-7491730-B2 | Compositions useful as inhibitors of GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-17 | — | — | US | disclosed |
| WO-2009018415-A1 | PROCESS FOR PREPARING 5-FLUORO-1H-PYRAZOLO [3, 4-B] PYRIDIN-3-AMINE AND DERIVATIVES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118278-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF GSK-3 | GSK3B, GSK3A, GSKIP | CYP1A2 3247/4885CYP2C19 3052/4885CYP3A4 3409/4885 |
| US-20120232275-A1 | PROCESS FOR PREPARING 5-FLUORO-1H-PYRAZOLO [3,4-B] PYRIDIN-3-AMINE AND DERIVATIVES THEREOF | GSK3B, GSK3A, GSKIP | CYP1A2 683/4885CYP2C19 541/4885CYP3A4 235/4885 |
| US-20100184980-A1 | Process for Preparing 5-Fluoro-1H-Pyrazolo [3,4-b] Pyridin-3-amine and Derivatives Thereof | GSK3B, GSK3A, GSKIP | CYP1A2 683/4885CYP2C19 541/4885CYP3A4 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.